Kintor shares plunge after hair-loss drug flops in clinical trials
The company’s drug has failed to show a significant hair-boosting effect in Phase III trials, dashing investors’ hopes for a ground-breaking treatment for baldness Key Takeaways: The disappointing test results…
Booster Shot for Brii Biosciences with First Covid Drug Launch
Brii Biosciences announced the commercial launch of its injectable Covid antibody treatment, which will be covered by government medical insurance in many parts of the country Key Takeaways: The antibody…
Could Covid Drugs Help Cure Financial Ills at Ascletis Pharma?
Ascletis Pharma has applied for U.S. FDA approval to start clinical trials on a new Covid drug, ASC10 Key Takeaways: Ascletis Pharma is ready to put its new Covid drug…
FAST NEWS: Junshi Biosciences Oral Covid Drug Wraps Up Trials, to Seek Sales Approval
The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) announced late Monday that VV116, an oral drug developed by its JunTop Biosciences unit for the early treatment of Covid-19, has reached the main endpoint…
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Yonghe Medical’s share repurchase gets results, but can’t hide a receding profit line
2279.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
HBM gets health boost from drug licensing deals
2142.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
FAST NEWS: Nomura takes up Kintor Pharma stake
9939.HK
- HighTide Therapeutics places big IPO bet on “affluenza” drug
